Active antiangiogenic therapy
US7556809B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2003 |
| Grant date | Jul 7, 2009 |
| Priority date | — |
| Expiry date | Sep 4, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55594
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.